The role and therapeutic implications of Shenfu cinjection in the treatment of sepsis

The role and therapeutic implications of Shenfu injection in the treatment of sepsis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2200006018

Enrollment

Unknown

Registered

2022-05-19

Start date

2021-08-19

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sepsis

Interventions

SFI group:shenfu injection

control group:5% glucose

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)18 years<age<75 years;(2)diagnosis with septic shock (3) SFI were not used within 24 hours after hostapilization (4) recuit in EICU within 24 hours

Exclusion criteria

Exclusion criteria: (1) hypersensitivity to SFI; (2) the administration of other type of chinese medicine (3)palliative and end-life stage patients (4)pregnant and lactating women (5) patients with myocadrdial infarction or acute coronary syndrome (6)long-term use of immunosuppressive drugs or hormonal drugs (7) Patients with advanced malignancies (8) participants or thier agents are unable or unwilling to sign the informed consent document.

Design outcomes

Primary

Measure	Time frame
28-day mortality;	—

Secondary

Measure	Time frame
Syndecan-1;sublingual microcirculation;Angiopoietin-1;IL-6;PCT;WBC;Endothelin-1;Angiopoietin-2;CRP;	—

Countries

China

Contacts

Public ContactXiong Jianfei

Renji Hospital, School of Medicine, Shanghai Jiaotong University

Jianfei_xiong@sina.com13917084841

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026